Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email |...
Bright and early this morning Insmed ($INSM) announced that its inhaled antibiotic Arikace hit its primary endpoint in a Phase III study and was awarded fast-track status at the FDA.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and Nesa Nourmohammadi (...
The company's stock price skyrocketed nearly 63% to $4.40 per share as of 12:07 p.m. ET after the announcement.
Shares of Insmed ($INSM) shot up on Friday after the company reported that the FDA has lifted a clinical hold on its trial of Arikace, an inhalable antibiotic for lung disease. Regulators had stepped
Insmed's regulatory woes with the cystic fibrosis drug Arikace are continuing this morning with the news that the FDA will not release its hold on the late-stage trial for the treatment and is now
Just seven months after completing its takeover of Transave, Insmed is reporting that the FDA has put a clinical hold on the Phase III trial of Arikace, a late-stage cystic fibrosis drug that had
Insmed's lead drug failed to show efficacy in a mid-stage clinical trial of a genetic condition called myotonic muscular dystrophy and investors swiftly hammered the stock, sending down shares more
The FDA and Insmed have hammered out a deal that will allow a limited number of patients with Lou Gehrig's disease to receive doses of Iplex. That drug is approved for growth hormone deficiency but
Merck signaled its clear intent to get aggressive about the biosimilar business with this morning's announcement that the pharma giant is buying Insmed's portfolio of follow-on biologics for $130